Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11881887 | 0.84 | ALDH1A1 (0.39) | DAOCES2CES1TSHRALOX5 | |
| SCHEMBL73588 | 0.82 | DAO (0.43) | DAOCES2CES1TSHRKIF11 | |
| SCHEMBL1421302 | 0.82 | DAO (0.43) | DAOCES2CES1TSHRKIF11 | |
| SCHEMBL7432298 | 0.82 | DAO (0.43) | DAOCES2CES1TSHRKIF11 | |
| SCHEMBL41617 | 0.82 | DAO (0.43) | DAOCES2CES1TSHRKIF11 | |
| SCHEMBL1492740 | 0.82 | DAO (0.43) | DAOCES2CES1TSHRKIF11 | |
| SCHEMBL599752 | 0.82 | DAO (0.43) | DAOCES2CES1TSHRKIF11 | |
| SCHEMBL6717951 | 0.81 | DAO (0.39) | DAOCES2CES1TSHRKIF11 | |
| Hydrochloric Acid SCHEMBL9402263 | 0.80 | DAO (0.42) | DAOCES2CES1TSHRKIF11 | |
| SCHEMBL11468485 | 0.79 | RAB9A (0.41) | TSHRSMN1; SMN2LMNACHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2327766-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-12-02 | — | — | EP | disclosed |
| EP-2319919-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-1576108-B1 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | BASF ENZYMES LLC (US) | 2015-07-08 | — | — | EP | disclosed |
| EP-2327767-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-04-29 | — | — | EP | disclosed |
| EP-2327765-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-04-01 | — | — | EP | disclosed |
| US-8906663-B2 | Nitrilases | VERENIUM CORPORATION (US) | 2014-12-09 | — | — | US | disclosed |
| CN-1849391-B | Nitrilases, nucleic acids encoding nitrilases, and methods of making and using the same | DIVERSA CORP | 2014-06-11 | — | — | CN | disclosed |
| US-20130177949-A1 | NITRILASES | VERENIUM CORPORATION (US) | 2013-07-11 | — | — | US | disclosed |
| EP-2115153-B1 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | BP CORP NORTH AMERICA INC (US) | 2013-06-05 | — | — | EP | disclosed |
| US-8334125-B2 | Nucleic acids encoding nitrilases | VERENIUM CORPORATION (US) | 2012-12-18 | — | — | US | disclosed |
| CN-1849391-A | Nitrilases, nucleic acids encoding nitrilases, and methods of making and using the same | DIVERSA CORP (US) | 2006-10-18 | — | — | CN | disclosed |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORPORATION | 2006-10-12 | — | — | US | disclosed |
| CN-1744899-A | Piperidine derivatives as CCR5 antagonists | SMITHKLINE BEECHAM CORP (US) | 2006-03-08 | — | — | CN | disclosed |
| EP-1578910-A2 | NITRILASES | DIVERSA CORPORATION (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1569646-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004054974-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| WO-2003000840-A2 | NITRILASES | DIVERSA CORPORATION (US) | 2003-01-03 | — | — | WO | disclosed |
| US-4675419-A | Process for preparing α-hydroxy-acids and compounds obtained by this process | SANOFI (FR) | 1987-06-23 | — | — | US | disclosed |
| US-4535092-A | Acylanilides having antiandrogenic activity | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-08-13 | — | — | US | disclosed |
| EP-0079191-A1 | Amide derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | CCR5, CCR1, CXCR3 | DAO 2638/4885CES2 1279/4885CES1 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.